← Human Trials & Peer-Reviewed Studies
Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation
Plain-language guide to PMID 25681034 (2015): randomized clinical trial study of Endothelin-1.
Key Facts
- PMID
- 25681034
- Journal
- Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- Year
- 2015
- Study type
- Clinical Trial
- Authors
- Akı ŞZ et al. (7 authors)
- DOI
- 10.1016/j.bbmt.2015.02.002
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Endothelin-1.
Graft-versus-host disease, iron overload, and infections are the major causes of liver dysfunction in allogeneic hematopoietic stem cell transplantation (AHSCT) recipients.
The researchers investigated the relationship between serum iron parameters and the levels of transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), endothelin-1 (ET-1), and nitric oxide (NO) as predictors of chronic liver injury in 54 AHSCT recipients who survived at least a year after transplantation.
Who Took Part
PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.
What Was Measured
The researchers investigated the relationship between serum iron parameters and the levels of transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), endothelin-1 (ET-1), and nitric oxide (NO) as predictors of chronic liver injury in 54 AHSCT recipients who survived at least a year after transplantation.
Serum samples from patients were obtained for the evaluation of ET-1, TGF-β, FGF, NO, and nontransferrin bound iron at the first year follow-up visit using commercially available ELISA kits.
The subject headings attached to it are Allografts, Endothelin-1, Fibroblast Growth Factors, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Iron and Iron Overload.
Author keywords: Graft-versus-host disease, Liver injury, Nitric oxide and Transforming growth factor-β.
What This Means in Plain Language
The paper is a randomized study of Endothelin-1.
The publication is from 2015 (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation), a journal based in United States.
More context: the Endothelin-1 compound page, all human trials.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.